HDT BIO
We are a biopharmaceutical company formed to address critical unmet needs to treat cancers and infectious diseases. In 2014, the U.S. market for immune therapeutics was estimated at $1.4 billion and it is projected to grow to $27 billion by 2021. Assets in our portfolio include activators of innate and adaptive immune responses. A distinguishing factor to these is the formulation expertise which enables these technologies by targeting them to local and systemic sites in the body where they ar... e needed. Since they affect the host and not the pathogen it will be difficult for resistance to emerge. Thus, we see an opportunity to apply the latest technologies in immunology to expand the benefits of immunotherapy to all. Our founders are world leaders in the development of adjuvants and immune therapeutics and have developed a number of these immune stimulants in the past in their work with multiple successful spin-out exits. They are joined by experienced entrepreneurs with expertise in biotechnology operations, finance, intellectual property, legal and strategy.
HDT BIO
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.hdt.bio
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
18.95 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail GoDaddy DNS
Similar Organizations
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
US Army
US Army investment in Grant - HDT Bio
National Institutes of Health
National Institutes of Health investment in Grant - HDT Bio
Eric Anschutz
Eric Anschutz investment in Seed Round - HDT Bio
Zoic Capital
Zoic Capital investment in Seed Round - HDT Bio
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - HDT Bio
Official Site Inspections
http://www.hdt.bio Semrush global rank: 3.11 M Semrush visits lastest month: 5.17 K
- Host name: gra.graphicainc.com
- IP address: 162.241.142.33
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "HDT Bio"
Our Team - HDT Bio
HDT Bio has created an ecosystem of leadership and expertise that will accelerate its products towards clinical valuation and global access. Careers at HDT Bio. We are proud of our …See details»
About Us - HDT Bio
HDT Bio is dedicated to combining for-profit goals with global health equity objectives. The company’s strategy emphasizes an integrative approach, generating platform and product …See details»
HDT Bio - Crunchbase Company Profile & Funding
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, …See details»
HDT Bio Company Profile 2025: Valuation, Funding
HDT Bio has raised $14.5M. Who are HDT Bio’s investors? National Institute for Allergy and Infectious Disease, Eric Anschutz, Mathew Spolin, Zoic Capital , and U.S. Department of Health and Human Services have invested in HDT Bio.See details»
HDT Bio Company Profile: Overview and Full News Analysis
HDT Bio, based in Washington, is a clinical-stage private company at the forefront of redefining the global vaccine landscape with its transformative repRNA vaccine platform. The company …See details»
HDT Bio - LinkedIn
HDT Bio | 5,663 followers on LinkedIn. Immune Therapy For All | HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and …See details»
HDT Bio - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Seed Round - HDT Bio . Eric …See details»
HDT Bio Corp. - Drug pipelines, Patents, Clinical trials - Synapse
Explore HDT Bio Corp. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 22 news, and 11 literature, Disease Domain:Infectious Diseases, Neoplasms, Immune System …See details»
HDT Bio - Contacts, Employees, Board Members, Advisors & Alumni
HDT Bio has 6 current employee profiles, including Chief Technology Officer Peter Berglund. Peter Berglund Chief Technology Officer Steven Reed Co-Founder & CEOSee details»
HDT Bio Company Profile - Office Locations, Competitors ... - Craft
HDT Bio has 5 employees at their 1 location and $11.3 m in total funding,. See insights on HDT Bio including office locations, competitors, revenue, financials, executives, subsidiaries and …See details»
HDT Bio - Products, Competitors, Financials, Employees, …
HDT Bio is a clinical stage biotechnology company focused on developing advanced RNA vaccine products for infectious diseases and cancers. The company's main offerings include a …See details»
Curt Malloy, JD, MPH | Profiles - Seattle University
Curt Malloy CV. Curt Malloy is the Senior Vice President, Strategic Operations at HDT.bio, a life science organization striving to promote health and well-being for everyone in the world, …See details»
HDT Bio To Make Corporate Presentation at BioFuture Investor …
SEATTLE, WA (November 1, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today CEO Steven Reed will give a corporate …See details»
MalarVx licenses HDT Bio's repRNA/LION™ Technology for Novel …
4 hours ago HDT Bio's LIONâ„¢ platform to support malaria vaccine development by MalarVx. SEATTLE, Jan. 15, 2025 /PRNewswire/ -- MalarVx, Inc., a clinical-stage vaccine company, is …See details»
HDT Bio to Help Spearhead RNA Vaccine Development in National …
Sep 17, 2024 HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud to announce its pivotal role in PROVIDENT …See details»
MalarVx licenses HDT Bio's repRNA/LION™ Technology for Novel …
4 hours ago HDT Bio's LION â„¢ platform to ... Malaria was responsible for 597,000 deaths and 263 million cases in 2023, according to the World Health Organization.See details»
Technology - HDT Bio
With LIONâ„¢, HDT Bio is committed to advancing global health by fighting infectious diseases and improving access to preventative healthcare for all. Cost-Effective Global Distribution This …See details»
MalarVx licenses HDT Bio's repRNA/LIONâ„¢ Technology for
1 day ago HDT Bio's LION â„¢ platform to ... Malaria was responsible for 597,000 deaths and 263 million cases in 2023, according to the World Health Organization.See details»
Human Digital Twins: A systematic literature review and concept ...
Our review reveals a consensus that an HDT’s twinned entity is a human individual. However, there is little agreement on the data flows between the individual and their HDT. ... Towards a …See details»
Pipeline - HDT Bio
Infectious Diseases. HDT Bio’s COVID-19 vaccine, HDT-301, is in Phase 1 clinical trial in the US. Other COVID-19 vaccines developed using HDT Bio’s AMPLIFY platform have been …See details»